What is Eagle Pharmaceuticals, Inc. (EGRX)?

Eagle Pharmaceuticals, Inc. (EGRX) is a stock in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry. View full analysis on Stocks360.

What is the current price of EGRX?

The current price of EGRX is $0.95. Prices are updated in real time on Stocks360.

What is EGRX's price-to-earnings (PE) ratio?

EGRX's trailing twelve-month PE ratio is 0.34, based on current price and earnings per share data available on Stocks360.

What is EGRX's market capitalization?

EGRX's market capitalization is $12,499,675.00, placing it in the small-cap tier.

Eagle Pharmaceuticals, Inc. (EGRX)

Stock analysis · OTC · Healthcare · Drug Manufacturers - Specialty & Generic

$0.95

Market Cap

$12.50M

PE (TTM)

0.34

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.66

Day Range

$0.00 – $0.98

52-wk Range

$0.05 – $3.87

Avg Volume

N/A

Volume

404.00

Eagle Pharmaceuticals, Inc. (EGRX) is a publicly traded company in the Healthcare sector. Latest price: $0.95. Market cap $12.50M. Trailing PE 0.34. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-29 · $0.70 2026-10-26 · $0.95 (+35.71%)

Earnings

Most Recent

Nov 9, 2023

EPS $-0.27 vs est. $1.09

Missed by $1.36

Next Earnings

Nov 9, 2026

EPS estimate $0.73

Proprietary Signals

Signal snapshot temporarily unavailable.

About Eagle Pharmaceuticals, Inc.

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company’s product portfolio offers RYANODEX for malignant hyperthermia; and BELRAPZO and BENDEKA for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma. It also produces PEMFEXY, a ready-to-dilute liquid form of pemetrexed injection, indicated in combination with cisplatin for the initial treatment of patients with malignant pleural mesothelioma and non-small cell lung cancer; BARHEMSYS, a selective dopamine-2 (D2) and dopamine-3 (D3) receptor antagonist indicated in adults for prevention of postoperative nausea and vomiting (PONV); BYFAVO, a benzodiazepine indicated for the induction and maintenance of procedural sedation in adults. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an anti-toxin agent in Phase 2 development for the treatment of severe pneumonia in combination with traditional antibacterial drugs; ENA-001 developed by Enal…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	0.34×
P/S (TTM)	0.04×
P/B	0.05×
P/FCF (TTM)	0.25×
EV / EBITDA	0.32×
EV / Sales	0.08×
Earnings Yield	290.07%
Free Cash Flow Yield	404.19%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$24.97M
Revenue (TTM)	$316.61M
Net Income (TTM)	$36.26M
Free Cash Flow (TTM)	$52.87M
Net Debt	$12.47M
Working Capital	$77.67M
Gross Margin	70.01%
Operating Margin	25.57%
Net Margin	11.26%
Return on Equity	17.39%
Return on Invested Capital	15.51%